Biological E. has been chosen by the World Health Organization's technology transfer hub to get mRNA technology. The WHO's Advisory Committee on Vaccine Product Development has chosen Biological E. as a beneficiary after reviewing a number of Indian bids, the Hyderabad–based firm announced on Monday. The WHO and partners will collaborate with the Indian government and Biological E to build a roadmap and provide training and assistance to the company so that it may begin producing mRNA vaccines as soon as possible, according to the statement. “We are very pleased with the trust WHO places in our organisation... this is also a reflection of our world–class processes, scale and effectiveness,” BE Managing Director Mahima Datla was quoted by News agency The Hindu.

Key Points

• Biological E. has been chosen by the World Health Organization's technology transfer hub to get mRNA technology. 

• The WHO and partners will collaborate with the Indian government and Biological E to build a roadmap and provide training and assistance to the company so that it may begin producing mRNA vaccines as soon as possible, according to the statement.

Follow Us On Google Newsstand: Click Here